Supplementary Table 4. Adjusted RRs Without Marital Status and Low-Income Subsidy.
Rate ratios (RRs) and 95% confidence intervals (CIs) (correspond to Aim 2 Table 2). Among women diagnosed with first primary invasive breast cancer between 2000-2017, captured in the SEER-Medicare database, with continuous fee-for-service Medicare coverage for at least 12 months prior and at least 3 months after index cancer diagnosis (n=215,605).

		Black	American Indian/Alaska Native	Asian/Pacific Islander	Hispanic White
Diagnostics					
Mammography	Adjusted[a]	0.95 (0.95-0.96)	0.94 (0.91-0.96)	**0.96 (0.95-0.97)**	**0.97 (0.96-0.98)**
Initial needle breast biopsy	Adjusted[a]	0.95 (0.94-0.96)	0.93 (0.9-0.96)	**0.98 (0.97-0.99)**	**0.98 (0.97-0.99)**
Clinical workup					
Node biopsy	Adjusted[a]	0.97 (0.96-0.98)	0.96 (0.94-0.99)	1.00 (0.99-1.01)	1.00 (0.99-1.01)
Stage known	Adjusted[a]	0.992 (0.987-0.996)	0.97 (0.95-0.99)	1.001 (0.99-1.01)	**0.99 (0.98-0.99)**
Grade known	Adjusted[a]	0.97 (0.97-0.98)	1 (0.98-1.02)	**1.02 (1.01-1.02)**	**0.99 (0.98-0.998)**
HR documentation	Adjusted[a]	0.98 (0.97-0.98)	0.98 (0.95-0.99)	1 (0.998-1.01)	**0.98 (0.97-0.99)**
HER2 documentation (n=94264)	Adjusted[a]	0.99 (0.99-1.0002)	0.98 (0.95-1.005)	1 (0.99-1.01)	**0.99 (0.98-0.998)**
Treatments					
Surgery	Adjusted[b]	**0.98 (0.98-0.99)**	0.98 (0.96-1.00)	1.00 (0.99-1.005)	1.00 (0.998-1.01)
Radiation among BCS-treated (n=106014)	Adjusted[b]	0.99 (0.98-1.01)	0.95 (0.9-1.001)	1.00 (0.99-1.02)	1.00 (0.99-1.02)
Radiation among mastectomy-treated N2+ or T3 (n=18755)	Adjusted[b]	1.01 (0.97-1.05)	0.99 (0.85-1.16)	1.03 (0.98-1.09)	1.00 (0.95-1.04)
Radiation among no surgery (n=18034)	Adjusted[b]	0.97 (0.89-1.05)	0.95 (0.68-1.35)	0.96 (0.83-1.11)	0.92 (0.81-1.05)
Chemotherapy among triple-negative (n=7853)	Adjusted[c]	**1.05 (1.01-1.1)**	0.99 (0.76-1.28)	1.01 (0.94-1.09)	1.06 (0.99-1.13)
HER2 among HER2+ (n=9641)	Adjusted[b]	**0.93 (0.88-0.99)**	0.8 (0.6-1.06)	1.04 (0.98-1.1)	1.05 (0.99-1.12)
Hormonal among HR+ (n=67116)	Adjusted[c]	1.00 (0.99-1.02)	**0.91 (0.85-0.98)**	**1.02 (1-1.04)**	1.01 (0.99-1.03)

[a]Adjusted model includes: hospitalizations, year, age, PCP count, NCI index, frailty. [b] Adjusted model includes: HR status, stage, and hospitalizations, year, age, PCP count, NCI index, frailty. [c] Adjusted model includes: stage and hospitalizations, year, age, PCP count, NCI index, frailty.
Bolded values reflect significant associations, with respect to non-Hispanic White patients, at the 0.05 significance level. HER2 status was first made available for cases diagnosed in 2010; HER2 status available refers to patients from the Primary cohort diagnosed 2010 or later. Part D eligible patients were those with at least three months of continuous Part D prescription drug coverage after diagnosis. Radiation was analyzed within subgroups of surgery type; mastectomy-treated patients were further restricted to patients for whom radiation with mastectomy is indicated (AJCC >=N2 or T3). Stage known refers to known clinical or pathologic stage. Abbreviations: Hormone receptor (HR), Human epidermal growth factor receptor 2 (HER2), Breast conserving surgery (BCS), HR-positive (HR+), HR-negative (HR-), HER2-positive (HER2+), HER2-negative (HER2-), Triple negative (HR- & HER2-).